RGEN Latest Headlines

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), OmniAb (OABI) and Incyte (INCY)

at www.tipranks.com (Mon, 2-Nov 11:30 AM)

Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN), OmniAb (OABI) and Repligen (RGEN)

at www.tipranks.com (Mon, 2-Nov 11:16 AM)

RBC Capital Remains a Buy on Repligen (RGEN)

at www.tipranks.com (Mon, 2-Nov 10:37 AM)

William Blair refreshes stock Conviction List with 5 additions, 3 removals

at seekingalpha.com (Mon, 2-Nov 8:56 AM)

Repligen–BioLife Deal Faces Market, Integration, and Regulatory Risks That Could Undermine Synergies and Long-Term Value

at www.tipranks.com (Sun, 1-Nov 1:00 AM)

Repligen Plans $1 Billion Convertible Notes Deal With a $226.37 Conversion Price and a $120 Million Share Repurchase

Market Chameleon (Fri, 30-Oct 11:51 AM)

J.P. Morgan Sticks to Their Buy Rating for Repligen (RGEN)

at www.tipranks.com (Fri, 30-Oct 8:50 AM)

Repligen announces $1 Billion private convertible senior notes transaction

at seekingalpha.com (Fri, 30-Oct 7:12 AM)

Repligen Announces New Convertible Notes and Capital Restructuring

at www.tipranks.com (Fri, 30-Oct 6:36 AM)

KeyBanc Reaffirms Their Buy Rating on Repligen (RGEN)

at www.tipranks.com (Thu, 29-Oct 3:46 AM)